Www.metcardio.org Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy...

38
www.metcardi o.org Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy [email protected] Educational Fellowship in PCI for Young Interventionalists - Certified Training Course (EAPCI, SCAI, GISE) - Bologna, 25/9/2008 – 14:30-17:30 (15’) LEFT MAIN/MULTIVESSEL DISEASE: LEFT MAIN/MULTIVESSEL DISEASE: WHEN PERCUTANEOUS CORONARY WHEN PERCUTANEOUS CORONARY INTERVENTION, WHEN SURGERY? INTERVENTION, WHEN SURGERY?

Transcript of Www.metcardio.org Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy...

www.metcardio.org

Giuseppe Biondi Zoccai

University of Turin, Turin, ItalyMETCARDIO, Turin, Italy

[email protected]

Educational Fellowship in PCI for Young Interventionalists -

Certified Training Course (EAPCI, SCAI, GISE) - Bologna, 25/9/2008 – 14:30-17:30 (15’)

LEFT MAIN/MULTIVESSEL DISEASE: LEFT MAIN/MULTIVESSEL DISEASE:

WHEN PERCUTANEOUS CORONARY WHEN PERCUTANEOUS CORONARY

INTERVENTION, WHEN SURGERY?INTERVENTION, WHEN SURGERY?

www.metcardio.org

LEARNING GOALS

• Should I bother with left main (LM)/ multivessel disease (MVD)?

• Who is the winner between PCI and CABG in LM/MVD?

• When is surgery appropriate for LM/MVD?

• When is PCI appropriate for LM/MVD?

www.metcardio.org

LEARNING GOALS

• Should I bother with left main (LM)/ multivessel disease (MVD)?

• Who is the winner between PCI and CABG in LM/MVD?

• When is surgery appropriate for LM/MVD?

• When is PCI appropriate for LM/MVD?

www.metcardio.org

PREVALENCE AND PROGNOSIS OF LM/MVD DISEASE

Chaitman et al, Circulation 1981;64:360-367; Yusuf et al, Lancet 1994;344:563-570;

Melidonis et al, Angiology 1999;50:997-1006

• Out of 1000 pts undergoing coronary angio: 30-80 will have unprotected LM, 20-60 protected LM, a total of 300-700 will have MVD

• Unprotected LM has, historically, a 36% 5-year mortality rate with medical Rx only, which is reduced to 12% after CABG (p=0.004)

• Corresponding figures for 3VD are 18% vs 10% (p<0.001), and for 2VD are 12% vs 10% (p=0.45)

• Whenever LV function is abnormal, 5-year mortality with medical Rx only is 25%, which is reduced to 14% after CABG (p=0.02)

www.metcardio.org

LEARNING GOALS

• Should I bother with left main (LM)/ multivessel disease (MVD)?

• Who is the winner between PCI and CABG in LM/MVD?

• When is surgery appropriate for LM/MVD?

• When is PCI appropriate for LM/MVD?

www.metcardio.org

WHO’S THE WINNER BETWEEN PCI AND SURGERY IN LM-MVD?

www.metcardio.org

ARE THEY ENEMIES OR FRIENDS?

www.metcardio.org

LET’S LOOK AT THE PAST…

www.metcardio.org

META-ANALYSIS OF RCTS OF CABG VS PCI: 5-YEAR-SURVIVAL WITH POBA VS BMS

Bravata et al, Ann Intern Med 2007;147:703-716

www.metcardio.org

META-ANALYSIS OF RCTS OF CABG VS PCI: 5-YEAR-SURVIVAL WITH POBA VS BMS

Bravata et al, Ann Intern Med 2007;147:703-716

www.metcardio.org

META-ANALYSIS OF RCTS OF CABG VS PCI: 5-YEAR-SURVIVAL IN DIABETICS

Bravata et al, Ann Intern Med 2007;147:703-716

www.metcardio.org

HOWEVER, PCI WITH BMS WAS INFERIOR TO CABG FOR THE

RISK OF REPEAT PCI/CABG

Biondi-Zoccai et al, Ital Heart J 2003;4:271-280

www.metcardio.org

WHAT ABOUT THE PRESENT…

www.metcardio.org

RISK OF MACE AT MID-TERM FOLLOW-UP FOLLOWING PCI WITH DES FOR ULM

Biondi-Zoccai et al, Am Heart J 2008;155:274-283

www.metcardio.org

IMPACT OF LESION LOCATION AND PATIENT RISK FEATURES ON OUTCOMES OF ULM PCI

Biondi-Zoccai et al, Am Heart J 2008;155:274-283

www.metcardio.org

SYNTAX REGISTRIES

Mohr et al, ESC 2008

PCI REGISTRY (N=192) CABG REGISTRY (N=644)

www.metcardio.org

SYNTAX TRIAL: 12-MONTH RESULTS

Serruys et al, ESC 2008

%

P=0.37 P=0.11 P=0.003

P<0.001

P=0.0015

P=0.89

www.metcardio.org

SYNTAX TRIAL: 12-MONTH MACES

Serruys et al, ESC 2008

www.metcardio.org

SYNTAX TRIAL: DM VS NON-DM

Serruys et al, ESC 2008

www.metcardio.org

LEARNING GOALS

• Should I bother with left main (LM)/ multivessel disease (MVD)?

• Who is the winner between PCI and CABG in LM/MVD?

• When is surgery appropriate for LM/MVD?

• When is PCI appropriate for LM/MVD?

www.metcardio.org

ESC 2005 GUIDELINES

Silber et al, Eur Heart J 2005;26:804-847

www.metcardio.org

ESC 2005 GUIDELINES

Silber et al, Eur Heart J 2005;26:804-847

THUS CABG IS RECOMMENDED INSTEAD OF PCI IN MOST CASES OF CAD IN

DIABETICS, IN MOST CASES OF MVD, AND ALL BUT A FEW CASES OF ULM…however, the guidelines are based mainly on

differences in repeat revascularization rate

www.metcardio.org

MY SURGICAL MUST DOs• Concomitant compelling indication to

cardiothoracic surgery (eg MR)

• Absolute contraindications to antiplatelet therapy

• Previous failed PCI attempts (especially LAD)

• Multivessel CTO or CTO

involving proximal-mid LAD

• Very high SYNTAX score (?!)

www.metcardio.org

WHAT ABOUT ITALIAN INTERVENTIONISTS?

Sheiban et al, Int J Cardiol 2008 – in press

Results of run-in survey for the RITMO Study on the management of unprotected left main disease in Italy (data limited to 2006)

RESPONDERSRESPONDERS NON-RESPONDERSNON-RESPONDERSNumber of centers 45 195Total coronary angiographies 61,370 198,906Coronary angiographies per center 1363±866 1036±630Total PTCA 31,699 92,392PTCA per center 704±479 499±308Total multivessel PTCA 7,870 19,947Multivessel PTCA per center 183±163 109±106Total PTCA with stenting 28,961 85,732PTCA with stenting per center 673±428 465±288Total PTCA with drug-eluting stenting 18,357 46,498PTCA with drug-eluting stenting per center 426±350 261±200ULM diagnosed at angiography per center, of total angio 5.0% (1.9-15.8) -ULM treated with CABG per center, out of total ULM at angio 50.0% (9.3-99.1) -ULM treated with PTCA per center, out of total ULM at angio 20.0% (0-80.8) -

www.metcardio.org

LEARNING GOALS

• Should I bother with left main (LM)/ multivessel disease (MVD)?

• Who is the winner between PCI and CABG in LM/MVD?

• When is surgery appropriate for LM/MVD?

• When is PCI appropriate for LM/MVD?

www.metcardio.org

CAN WE CAN DO WHATEVER THE SURGEON DOES?

www.metcardio.org

CAN YOU DO IT?

85-year-old 85-year-old ♂ with with non-STEMI and non-STEMI and true trifurcational true trifurcational unprotected LM unprotected LM disease, high disease, high

surgical risk and surgical risk and LVEF 45%LVEF 45%

www.metcardio.org

ACTUALLY, IT CAN BE DONE,

BUT SHOULD I DO IT?

BEFORE PCIBEFORE PCI AFTER PCI WITH AFTER PCI WITH 4 STENTS4 STENTS

Sheiban et al, Catheter Cardiovasc Interv 2008 – in press

www.metcardio.org

ESC 2005 GUIDELINES

Silber et al, Eur Heart J 2005;26:804-847

www.metcardio.org

ESC 2005 GUIDELINES

Silber et al, Eur Heart J 2005;26:804-847

THUS THE ROLE OF PCI IS LIMITED IN MOST CASES OF CAD IN DIABETICS, IN MOST CASES OF MVD, AND ALL BUT A FEW CASES OF ULM

…however, the guidelines are based mainly on differences in repeat revascularization rates

www.metcardio.org

MY PCI MUST DOs• Previous CABG (especially if redo already

performed and/or LIMA already there)

• Prohibitive surgical risk (with compelling indication)

• FFR unmasks MVD as just SVD

• Ongoing STEACS with culprit lesion amenable to primary PCI

• Patients refuses CABG (?!)

but provided patient and referring colleagues are consenting!

www.metcardio.org

MY EQUIPOISE• Non-bifurcational ULM with high surgical risk

• Multivessel but focal disease with only A-B2 lesions, or non-challenging C lesions

• Good LV function

• Very young or very old

• Depending also on need for and likelihood of completeness of revascularization

but still provided patient and referring colleagues are consenting!

www.metcardio.org

TAKE HOME MESSAGES

www.metcardio.org

MY PRACTICAL FLOWCHARTULM or 3VD with any of the following unfavorable features:•True bifurcational disease of ULM•1 or > clinically relevant CTO•LV dysfunction (LVEF<40%)•Inexperienced operator (<1000 PCI)•Other surgical indications

CABG as first choice! Attempt PCI only if:• CABG contraindicated and• Patient/family and cardiac surgeon

agree on PCI

CABG favored, but PCI reasonableULM or 3VD without unfavorable features

Risk-benefit balance supports PCI, but CABG should still be

considered and discussed with patient and family

Protected LM/2VD with any of these “favorable” features :•Ostial LAD is ok•Lack of diffuse disease•No true bifurcations•No CTO•Ongoing STEACS

www.metcardio.org

A. 1ST STEP IN CRISIS MANAGEMENT IS PREVENTING THE CRISIS: FOLLOW

GUIDELINES UNLESS YOU ARE JUSTIFIED …

www.metcardio.org

B. COLLABORATIVE DECISON-MAKING IN ALL BUT CLEAR-CUT CASES: INVOLVE OTHER INTERVENTIONAL COLLEAGUES, NON-INVASIVE CARDIOLOGISTS, AND SURGEONS

www.metcardio.org

C. NEVER FORCE TOO MUCH…EITHER INDICATIONS, DEVICES, TECHNIQUES, OR ANCILLARY THERAPY (EG ANTI-THROMBOTIC RX)

www.metcardio.org

For further slides on these topics please feel free to visit the

metcardio.org website:

http://www.metcardio.org/slides.html